Summary of Key Information:

Reporting Period (Quarter/Year): Not Specified

Nature of Filing / Announcement: Outcome of Board Meeting under SEBI Listing Regulations

Audit Opinion:

Not Specified

Key Financial Highlights:

Not Specified

Standalone Results:

Not Specified

Consolidated Results:

Not Specified

Segment-wise Performance:

Not Specified

Corporate Actions:

Not Specified

Director Profiles:

Mr. Udo Jahannes Vetter: Earned degree in Clinical Pharmacy from University of Washington. Previously worked as Manufacturing Pharmacist at Schering Plough Corp. (now Merck & Co., Inc.). Served in various leadership roles including Managing Director of Vetter Pharma and Vetter Inject GmbH & Co. KG. Currently serves as Chairman of the ITM Group, Germany. Member of International Society for Pharmaceutical Engineering (ISPE) and Global Pharmaceutical Manufacturing Leadership Forum (GPMLF). Vice-President of European Family Businesses (EFB) Association.

Mr. William Robert Keller: Aged 78, currently Independent Director of Wuxi Biologics Limited and Hua Medicine. Previously Director of Cathay Biotech Inc (2020-2025) and Chairman of Coland Pharmaceutical Co. Ltd (10 years until November 2020). Independent Director of Alexion Pharmaceuticals Inc. (2009-2015) and Taigen Biopharmaceutical Holding Limited. Over 40 years of experience managing operations in South America and Asia with Roche, including Managing Director of Roche Hong Kong (1990-1994) and General Manager for Roche China Holding (1994-2003). Founded Keller Pharma Consultancy in 2003. Holds Bachelor of Science degree from School of Economics and Business Administration in Zurich, Switzerland (1972).

Committee Composition Changes (Effective June 15, 2026):

Audit Committee:

  • Essaji Goolam Vahanvati - Chairman & Independent Director
  • William Robert Keller - Independent Director (replacing Mr. C.S.N. Murthy)
  • Udo Johannes Vetter - Independent Director

Nomination & Remuneration Committee:

  • Udo Johannes Vetter - Chairman & Independent Director
  • Essaji Goolam Vahanvati - Independent Director
  • William Robert Keller - Independent Director (replacing Mr. C.S.N. Murthy)
  • Ms. Wei Huang – Non-Executive Director

Risk Management Committee: No changes

  • Naina Lal Kidwai - Chairperson & Independent Director
  • Srinivas Sadu- Executive Chairman
  • Dr. Jia Ai Zhang - Non-Executive Director
  • Ravi Shekhar Mitra- Chief Financial Officer

Stakeholders' Relationship Committee & Share Transfer Committee:

  • Udo J Vetter - Chairman & Independent Director (replacing Mr. C.S.N. Murthy)
  • Srinivas Sadu- Executive Chairman & CEO
  • Wenjie Zhang- Non-Executive Director

Corporate Social Responsibility Committee: No changes

  • Srinivas Sadu- Chairman & Executive Chairman
  • Essaji Goolam Vahanvati- Independent Director
  • Dr. Jia Ai Zhang- Non-Executive Director

ESOP Compensation Committee:

  • Udo J Vetter- Chairman & Independent Director
  • Essaji Goolam Vahanvati- Independent Director
  • Srinivas Sadu- Executive Chairman (replacing Mr. C.S.N. Murthy)

Material Subsidiary Board Composition:

Gland Pharma International Pte. Ltd Board of Directors as of June 15, 2026:

1. Mr. Srinivas Sadu

2. Mr. Essaji Goolam Vahanvati

3. Mr. Wu Rong (Mr. Raymond Wu)

4. Ms. Liao Rong (Ms. Carol Rong)

Other Significant Information:

The company will obtain member approvals for director appointments through postal ballot and e-voting as required under SEBI Listing Regulations Regulation 17(1A), 25(2A), and 17(1C).